Gene therapy is changing the way we think about healthcare and treatments for chronic diseases—and for self‑funded employers, it’s bringing serious financial shock potential. With many therapies priced between $2 million and $4 million per treatment, a single claim can throw an entire plan year off balance [1–4]. Additionally, as the number of FDA‑approved cellular and gene therapies keeps climbing, traditional stop‑loss coverage isn’t built to handle this level of volatility anymore [5, 6].
That’s why Planned Administrators, Inc. (PAI)—in partnership with SBR and the Association for CGT Solutions—created a purpose‑built Gene Therapy Stop‑Loss Solution. It’s designed to take the guesswork (and sticker shock) out of million‑dollar claims by helping employers:
In short, it’s the protection self‑funded employers need as gene therapy becomes more common—and far more expensive [5].
Gene therapies are delivering life‑changing outcomes for conditions that once had no real treatment options, but the price tags are just as dramatic [5].
Industry forecasts suggest U.S. gene therapy spend could reach ~$18.5B by 2033 [10, 11]. As more therapies make it through the FDA pipeline, employer exposure grows—often without the historical claims data on which underwriters rely [5, 6].
That creates a tough reality for self-funded health plans:
In other words, gene therapy brings incredible clinical value, but also unprecedented — and unpredictable — financial risk[ 5].
For self‑funded employers, the true cost of gene therapy goes far beyond the drug’s list price. While these treatments offer incredible clinical benefits, they also come with high‑cost claims that can overwhelm traditional stop‑loss coverage, and total exposure often rises when facility fees, conditioning/administration, and care coordination are included [13].
Real‑world price points (therapy list/WAC):
Note on administration/ancillary costs: Exact amounts vary by site of care, protocol, and patient factors; plans should expect additional six‑figure costs in many cases. [13].
Bottom line: gene therapy claims can exceed traditional stop‑loss thresholds quickly, reshaping a plan’s financial trajectory and impacting renewal pricing [8, 6].
Stop‑loss insurance is still a critical safety net for self‑funded employers—but the rise of gene therapy and other ultra‑high‑cost claims has exposed serious gaps in traditional models [8].
Here’s what today’s market data makes clear:
High‑cost claims are now blowing past deductibles, because most of these therapies are new, there’s no historical data to guide accurate underwriting. Carriers are being forced to price forward, building assumptions into renewals that may or may not match actual risk [6].
Specialty medications, orphan drugs, and FDA‑approved gene therapies are all driving a sustained rise in $1 million+ claims [12].
After a catastrophic claim—or even the potential for one—stop‑loss premiums can spike dramatically. This makes budgeting unpredictable, especially for mid‑sized and self‑funded employers trying to maintain plan stability [8].
What’s needed now: a gene‑therapy‑ stop‑loss solution built specifically to handle the speed, scale, and financial impact of million‑dollar CGT claims [7, 18].
PAI + SBR’s CGT Solution**
The Comprehensive Gene Therapy (CGT) Solution from PAI and SBR is built specifically to manage the financial exposure tied to gene therapy claims—one of the fastest‑growing and most unpredictable cost categories for self‑funded employers.
2026 Program Cost: $4.05 PEPM (eligibility, underwriting, and program terms apply) [20].
This fixed PEPM rate provides straightforward, predictable protection against multimillion‑dollar CGT claims, helping stabilize budgets and reduce renewal volatility [7].
The CGT Solution uses a first‑dollar coverage structure, which means protection kicks in from the start of a covered gene therapy claim [7].
Here’s how the process works:
Step 1: The plan incorporates a pre-treatment provision into their plan document with contact information for a designated CGT Program Manager.
When a covered gene therapy is anticipated the rendering provider contacts the CGT Program manager and a pre-treatment review is completed.
Step2: The CGT Program Manager responds
Coordination of care through a Center of Excellence (COE) provider designated by the CGT Program Manager.
Step 3: The ACGT Reinsurance Program reimburses
The ACGT Reinsurance Program steps in and reimburses:
The plan for claims paid up to the specific fee scheduled amounts noted in the ACGT reinsurance policy. The end result: catastrophic gene therapy exposure is mitigated before it impacts the employer’s balance sheet [7].When a candidate for gene therapy case is identified—whether covered or not—PAI and SBR provide hands‑on support to brokers, employers, and members:
If the reinsurance program covers the therapy, early identification of candidates, review and oversight must begin immediately, helping streamline the process, prevent delays, and avoid downstream disruption for the employer and member [13].
For employers using captive insurance or reinsurance, the CGT Solution fits smoothly into layered risk models. This flexibility becomes especially important when gene therapy claims can exceed $2.5 million [8]. Distributing risk across multiple layers, employers can reduce financial shock, protect captive performance, and maintain long‑term plan stability [6].
FDA‑approved gene therapies are increasing every year and stop‑loss underwriting is shifting just as quickly. Carriers are now pricing ahead of utilization, renewals are becoming harder to predict, and employers without CGT-specific protection face growing exposure [21, 6]
Proactively adopting gene therapy reinsurance coverage helps employers:
Waiting for the first claim is no longer a workable approach [8], early adoptionon a pre-service basis for a potential candidate is the only way to stay ahead of rapidly rising gene therapy risk.
Gene therapy is changing the landscape of catastrophic claims. But with PAI’s administrative expertise, SBR’s CGT Solution, and support from the Association for CGT Solutions, employers finally have a gene‑therapy‑specific stop‑loss strategy built for today’s cost and risk realities [19, 22].
You don’t have to absorb the impact. You can prevent it.
→ Learn More About the Gene Therapy Stop‑Loss Solution
→ Connect With PAI
Footnotes